Onkologie. 2014:8(6):257-258

Molecular genetics in gastrointestinal stromal tumors

Magdalena Uvírová1,2, Jarmila Šimová1,2, Barbora Kubová2, Jana Žmolíková1,2, Irena Urbanovská1,2, Jana Dvořáčková1,2,3, Arnošt Martínek1,4, Dušan Žiak1, Petr Dítě1,2,4
1 Lékařská fakulta Ostravské univerzity v Ostravě
2 CGB laboratoř a.s., Ostrava
3 Ústav patologie FN Ostrava
4 Interní klinika FN Ostrava

Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors of the gastrointestinal tract (GI) arising from the interstitial cells of Cajal,

primarily of the stomach and small intestine. During the past decade came up to progress of molecular targeted therapies for many

solid tumors and in association with discovery of onkogenic kinase mutations in GISTs to rapid evolution in understanding of molecular

biology features of these tumors and to implementation tyrosine kinase inhibitors in clinical practice. Therefore molecular genotyping

of this lesions is very important for prognosis, therapy, primary or secondary resistence to targeted therapy respectively.

Keywords: Gastrointestinal stromal tumor, mutation, KIT gene, PDGFRA gene

Published: December 15, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Uvírová M, Šimová J, Kubová B, Žmolíková J, Urbanovská I, Dvořáčková J, et al.. Molecular genetics in gastrointestinal stromal tumors. Onkologie. 2014;8(6):257-258.
Download citation

References

  1. The ESMO/European Sarcoma Network Working Group, Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up., Annals of Oncology 23 (Supplement 7)vi49-vi55,2012doi: 10.1093/annonc/mds252. Go to original source... Go to PubMed...
  2. Christopher L Corless, Gastrointestinal stromal tumors: what do we know now?, Modern Pathology (2014)27, S1-S16. Go to original source...
  3. Le Cesne Axel, Domont Julien, Blésius Aurore, Cioffi Angela, Mutational Analysis in gastrointestinal Stromal Tumors, EJCMO 2011;3: (1).February 2011.
  4. GENETICS HOME REFERENCE http://ghr.nlm.nih.gov.
  5. Lian Zong and Ping Chen, Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis, Journal of Surgical Oncology 2014; 12: 71. Go to original source... Go to PubMed...
  6. Heikki Joensu, MD; Mikael Erikson, MD; Kirsten Sundby Hall, MD; Jörg Hartmann, MD; Daniel Pink, MD; Jochen Schütte, MD; Giuliano Ramadori, MD; Peter Hohenberger, MD; Justus Duyster, MD; Salah Eddin Al-Batran, MD; Marcus Schlemmer, MD; Sebastian Bauer, MD; Eva Wardelmann, MD; Maarit Sarlomo-Rikala, MD;, Bengt Nilsson, MD; Harri Sihto, PhD,; Karla V.Ballman, PhD; Mika Leinonen, MSci; Ronald P. DeMatteo, MD; and Peter Reichardt, MD, Risk Factors for Gastrointestinal Stromal Tumor Reccurence in Patients treated With Adjuvant Imatinib, Cancer, Month 00,2014.
  7. Sosipatros A. Boikos, MD: Current Concepts, New Perspectives on the Genetic Basis of GISTs Lacking KIT and PDGFRA Mutations. The GIST Cancer Journal, Volume 1, Number 2 Spring 2014, www.thegistcancerjournal.org.
  8. Leona A Doyle & Jason L Hornick: gastrointestinal stromal tumors: from KIT to succinate dehydrogenase, Histopathology 2014, 64, 53-67.DOI: 10.111/his.12302. Go to original source... Go to PubMed...
  9. Gao X, Shen K, Wang C, Ling J, Wang H, Fang Y, Shi Y, Hou Y, Qin J, Sun Y, Qin X.: MiR -320a downregulation is associated with imatinib resitance in gastrointestinal stromal tumors., Acta Biochim Biophys Sin (Shanghai). 2014; 46(1): 72-75. doi: 10.1093/abbs/gmt118. Epub 2013 Nov 10. Go to original source... Go to PubMed...
  10. Susie Bae and Jayesh Desai: Personalised Management: Inoperable Gastrointestinal Stromal Tumors, Clinical Gastroenterology and Hepatology 2014; 12: 130-134. Go to original source... Go to PubMed...
  11. Ju-Han Lee, Younghye Kim, Jung-Woo Choi, Young- Sik Kim. Correlation of Imatinib Resistance with the Mutational Status of KIT and PDGFRA Genes in Gastrointestinal Stromal Tumors: a Meta-analysis.
  12. Jurečková A, Kocáková I, Vyzula R. Klinický registr GIST, Klin Onkol 2012; 25(2): 135-138. Go to PubMed...
  13. KimWK, Yang HK, Kim H. MicroRNA involvement in gastrointestinal stromal tumor tumorigenesis., Curr Pharm Des.2013; 19(7): 1227-1235. Go to original source...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.